In ccRCC, we found compelling CNV gain for CAMK2A, while PER2, PER3, ECE1, MAP2, and MTNR1A were dominantly CNV loss (Figure S2A). This evidence concerns the gene MAP2 and nonpapillary renal cell carcinoma.